C00-D48 M05-M14 M30-M36 M45 M46 M60 M65 L40.5
Conditions
Interventions
Group 1: Retrospective and prospective observation of routine care according to established clinical standards of cases (patients suffering from concomitant rheumatic disease / toxicities and malignan
Sponsors
Universitätsklinikum Heidelberg, Innere Medizin V
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • RheuMal (Rheumatologic patients with malignancy): patients suffering from concomitant rheumatic disease and malignancy and/or premalignant conditions. • TRheuMa (Therapy-induced rheumatic symptoms in patients with malignancy): patients suffering from rheumatic symptoms as a result of checkpoint inhibitors or other cancer therapies. • ParaRheuMa (Paraneoplastic rheumatic symptoms in patients with malignancy): patients suffering from paraneoplastic rheumatic symptoms due to a malignancy. • Control group: Matched patients suffering from either a malignant or a rheumatic disease at risk for developing the other disease entity / symptom complex. • Informed consent obtained
Exclusion criteria
Exclusion criteria: • Inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of linkages and interdependencies between malignant and rheumatic diseases from three different dimensions: -RheuMal (Rheumatologic patients with malignancy): Coincidence of rheumatic diseases with certain tumor entities and interrelationship between immunosuppressive therapy regimes and risk of malignancy / relapse. -TRheuMa (Therapy-induced rheumatic symptoms in patients with malignancy): systematic overview of the incidence, prevalence, characteristics and outcome of side effects of antineoplastic therapy regimes with focus on immune-related adverse events (irAEs) triggered by checkpoint-inhibitors. -ParaRheuMa (Paraneoplastic rheumatic symptoms in patients with malignancy): Correlation of paraneoplastic symptom complexes with certain tumor entities. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Cover and characterize the entire spectrum of possible malignant and rheumatic diseases. • Gather data on individual disease course and outcome to expand the knowledge base on clinical management. • Correlate data with established registries for patients with malignant or rheumatic disease. • Case-control approach with matched patients at risk to verify hypotheses on individual risk factors for developing malignancy or rheumatic symptom complexes as side effects of certain antineoplastic therapy regimes. • Collaboration with existing immunologic and biobank projects to correlate clinical and serological parameters and identify novel biomarkers and therapeutic targets. | — |
Countries
Germany
Contacts
Public ContactKarolina Gente
Universitätsklinikum Heidelberg, Innere Medizin V
Outcome results
None listed